Publication
Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancer.
Jingkun Li, Xinhao Han, Yan Zhuang, Yinting Liu, Samantha M Thomas, Jennifer K Plichta, Jinsong Wang, Bo Lei
Breast (Edinburgh, Scotland)Oct 1, 2026PMID 42659874doi:10.1016/j.breast.2026.104906 PMC13545399Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Oncotype DX testing guides adjuvant chemotherapy decisions in early-stage hormone receptor-positive/HER2-negative breast cancer, but testing is not universally performed, and outcomes associated with genomic-informed versus clinicopathologic-based chemotherapy decision pathways remain…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Breast Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.